Novocure (NVCR) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update
October 28, 2021 6:30 AM EDTQuarterly net revenues of $133.6 million with 77% gross margin
Last patient enrolled in phase 3 pivotal INNOVATE-3 trial for recurrent ovarian cancer
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2021, highlighting commercial strength and strategic investment across clinical, product development and commercial initiatives intended to fuel future growth. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). TTFields are electric fields that disrupt cancer... More
